

Index

- α-fetoprotein (αFP) 116, 120
- ABVD chemotherapy, in Hodgkin's disease
 - alternating with MOPP 199–200, 205–7
 - v MOPP 199–200, 203–5
 - v MOPP plus ABVD 200–1, 208
- A-COP chemotherapy, in NHL 163, 170–1
- A-COPP chemotherapy, in Hodgkin's disease 200–1, 211–12
- actinomycin D
 - in rhabdomyosarcoma 5
 - in Wilms' tumour 66–7, 74–6, 91
 - fractionated v single dose 73–4, 81–4, 88–9
 - see also bleomycin/cyclophosphamide/actinomycin D;
vincristine-containing regimens
- acute lymphoblastic leukaemia (ALL)
 - CNS directed therapy 340–91, 392–9
 - Cancer and Leukaemia Group B trial (CALGB) 356–78
 - Dana Farber Cancer Institute (DFCI) 87-01 and 91-01 protocols 335–9
 - radiotherapy trials 327–34
 - see also under cranial irradiation; intrathecal chemotherapy; craniospinal irradiation
 - continuing (maintenance) therapy 272–4, 400–51
 - dose and route of methotrexate 423–6
 - duration studies see duration of continuing therapy (below)
 - re-induction therapy 413–17
 - schedules of therapy 426–35
 - type of thiopurine 436–7
 - vincristine/prednisolone pulses see vincristine/prednisolone pulses (in ALL)
 - duration of continuing therapy 400–18
 - AIEOP trials 410–11
 - Berlin-Frankfurt-Munster (ALL-BFM) trials 417–18
 - Childhood ALL Collaborative Group 378–99, 413–16
 - Children's Cancer Study Group (CCG) studies 403–4, 407–10
 - Medical Research Council (UKALL) trials 400–3, 405–6, 411–13
 - European Organisation for Research and Treatment of Cancer (EORTC) trial study 186–7, 187–9
 - intensification 270
 - remission induction therapy
 - St. Jude's Total Therapy Study XI protocol 279–83
 - Memorial Sloan-Kettering New York protocol II 283–5
 - UK Medical Research Council ALL97 285–95
 - Children's Cancer Group (CCG) trials 295–302, 312–18
 - Tokyo Children's Cancer Study Group (TCCSG) trial L95-14 302–11
 - European Organization for Research and Treatment of Cancer – Children's Leukemia Group (EORTC-CLG) trial 319–23
 - Dutch Leukemia Study Group (DLSCG) 324–6
 - T cell (T-ALL) 164, 184–5
 - see also lymphoblastic lymphoma
- acute myeloid leukaemia (AML) 223–6
 - induction therapy 223–4, 227–39
 - Berlin-Frankfurt-Munster (BFM) 93 Study 223, 227–9
 - Children's Cancer Group (CCG) trials 223, 229–32, 236–9
 - Medical Research Council (MRC) AML-10 trial 223, 233–6
 - maintenance therapy 225, 236–9, 250
 - Children's Cancer Group Study 254–8
 - LAME 89/91 trial 250–4
 - post remission management 224, 240–9
 - AIEOP Cooperative Group study 240–2
 - Children's Cancer Group (CCG) study 247–9
 - Medical Research Council (MRC) AML-10 study 224, 244–7
 - Pediatric Oncology Group study 242–4
 - secondary 233, 244–5

- acute myeloid leukaemia (*Contd*)
 in Hodgkin's disease 206, 208–9, 212
 in NHL 164, 178
- acute promyelocytic leukemia (APL)
 APL 93 trial 258–61
 GIEMA-AIEOP AIDA trial 262–6
- ADCOMP chemotherapy, in NHL 164, 177–8
- ADE chemotherapy, in AML 227–9, 233–6
- Adriamycin *see* doxorubicin
- AIDS, transfusion related 136
- AIE chemotherapy, in AML 227–39
- ALL *see* acute lymphoblastic leukaemia
- allergic reactions, in NHL 184–5
- allogeneic bone marrow transplant (Allo BMT),
 in AML 224, 254
 AIEOP Cooperative Group study 240–2
 Children's Cancer Group (CCG) trials 232, 236–8,
 247–9
 Medical Research Council (MRC) AML-10 trial 224,
 233–6, 244–7
- all-trans retinoic acid (ATRA), in APL 258–61
- all-trans retinoic acid with idarubicin (AIDA),
 in APL 262
- amifostine, in cardioprotection 456
- AML *see* acute myeloid leukaemia
- amphotericin B, in ALL 460, 472, 473, 478, 486, 502
- amsacrine, in AML 240
- anthracycline administration, continuous infusion *v*
 bolus 548–51
- anthracycline induced cardiac damage 456
- anthracyclines
 in AML 223
 in non-lymphoblastic lymphoma 189–91
see also daunorubicin; doxorubicin; idarubicin
- anti-GD2 monoclonal antibody, in neuroblastoma 99
- AOPE chemotherapy, in Hodgkin's disease 200, 209–10
- ARA-C *see* cytosine arabinoside
- ASNase antibodies, ALL 315–16
- asparaginase
 in ALL 269–70, 279, 303, 312–26, 335, 356–7, 413–7,
 460, 476, 485, 548
 in AML 250
 in NHL 164, 166, 182–5
see also ADCOMP chemotherapy
- aspartic acid, in ALL 316–17
- ATRA syndrome, in AML 259
- astrocytoma
 anaplastic (AA) 150
 chemotherapy 152, 153, 156–7, 158–60
 radiotherapy 157–8
 surgery 150
 chemotherapy 153, 160–1
- surgery 150
see also glioma
- autologous bone marrow transplant (ABMT)
 in AML 230, 240–9
 AIEOP Cooperative Group study 240–2
 Children's Cancer Group (CCG) trial 232, 247–9
 Medical Research Council (MRC) AML-10 trial 224,
 233–6, 244–7
 Pediatric Oncology Group study 242–4
 in glioma 154
 in neuroblastoma 93–5, 99, 101–4, 104–6
- autologous hemopoietic stem cell transplantation
 (AHSCT), in ALL 467–8
- azacytidine, in AML 243
- BAVC chemotherapy, in AML 240
- BCD chemotherapy, in osteosarcoma 29, **30**, 33–4, 37–8,
 41–3
- B cell lymphoma 164, 175–7
- B-cell neoplasms
 BFM group study 195–8
- BCNU
 in AML 240
 in glioma 154
 in neuroblastoma 129–30
- bleomycin
 in Hodgkin's disease 200–1, 210–12
 in malignant germ cell tumour 116, 117, 121
see also ABVD chemotherapy
- bleomycin/cyclophosphamide/actinomycin D (BCD),
 in osteosarcoma 29, **30**, 33–4, 37–8, 41–3
- bleomycin/etoposide/cisplatin (BEP), in malignant germ
 cell tumour 116
- blood–brain barrier disruption
 in glioma 154
 in medulloblastoma 132
- bone marrow
 aplasia, in AML 228, 239
 histocompatible sibling donors 224
 minimal residual disease, in neuroblastoma 98
 purging, in neuroblastoma 93–4, 98, 101–4
 suppression *see* myelosuppression
 transplant (BMT) *see* allogeneic bone marrow
 transplant; autologous bone marrow transplant
- boys, duration of ALL therapy 400–1, 403, 407
- bradykinin analog, in glioma 154
- brain stem
 glioma (intrinsic pontine glioma) 150
 chemotherapy 153, 160–1
 radiotherapy 151, 157–8
 medulloblastoma involving 133, 134, 136
- brain tumours 125, 150

- secondary 271
see also astrocytoma; ependymoma; glioma; medulloblastoma
- bronchiolitis obliterans 184
- Burkitt lymphoma 167, 175, 178
- busulphan
 in AML 230, 233, 243, 246, 247
 in solid tumours 502
- camptothecins, in neuroblastoma 95
- carboplatin
 in ALL 504
 in glioma 153, 154, 161
 in hepatoblastoma 115
 in malignant germ cell tumour 116, 117
 in neuroblastoma 96, 101–4, 108–9
- cardiac toxicity
 in Ewing's sarcoma 53, 54
 in hepatoblastoma 119
 in Hodgkin's disease 201, 205, 206, 212
 in NHL 171
 in rhabdomyosarcoma 8
 in sarcoma
 left ventricular ejection fraction (LVEF) 543
 MUltiple Gated Acquisition (MUGA) scan 542, 543
 in Wilms' tumour 80
- cardiac troponin T, in ALL 538, 539–41
- cardioprotection
 in ALL
 Dana Farber Cancer Institute (DFCI) 538–42
 Dana Farber 91-01 Acute Lymphoblastic Leukemia protocol 548–51
 in sarcoma
 National Cancer Institute (NCI) protocol 86C169 542–7
- carmustine
 in AML 240
 in NHL 166
- carvedilol, in cardioprotection 456
- CCNU
 in medulloblastoma 129–30, 133–4, 144–6
see also CVPP chemotherapy; vincristine/CCNU/prednisone
- CCVP chemotherapy, in Hodgkin's disease 200
- CD30 (KI-1 antigen) 165
- ceftazidime, in ALL 478
- central nervous system (CNS) directed therapy 271–2
 in ALL 327–91
 in AML 230, 236, 240, 244–6
 in NHL 185–6
see also cranial irradiation; craniospinal irradiation; intrathecal chemotherapy
- central nervous system (CNS) tumours *see* brain tumours
- chemoembolisation, in hepatoblastoma 116
- chemotherapy
 in APL 258
 in glioma 151–3
 high-dose
 in AML 224
 in glioma 153–4
 in malignant germ cell tumour 115–16
 in neuroblastoma 93–5, 101–4
 in Hodgkin's disease 214–15
 intrathecal *see* intrathecal chemotherapy
 in medulloblastoma 126, 148
 radiation sensitising, in glioma 154
 “sandwich”, in medulloblastoma 129, 134–6, 139–40, 144–6
 in sarcoma, doxorubicin treated 543, 544
see also specific cytotoxic agents and regimens
- chemotherapy dose intensity (CDI)
 in GCSF 466–71
 in Ewing's sarcoma 60–1
- CHOP chemotherapy, in NHL 163, 181
- chromosomal translocations, in Ewing's sarcoma 50
- cisplatin
 in glioma 157–8
 in hepatoblastoma 115–16, 118–20
 in malignant germ cell tumour 116–17, 121
 in medulloblastoma 129, 144–6
 in neuroblastoma 98, 101–4, 104–6, 113, 527
 continuous *v* bolus infusion 98, 109–10
 plus teniposide 96, 108
 in osteosarcoma 29, 30, 31–3, 37–8, 46
 intra-arterial delivery 31, 32, 39–40
 in rhabdomyosarcoma 4, 12–14
- cisplatin/doxorubicin (PLADO)
 in hepatoblastoma 115–16, 118–20
 in osteosarcoma 27
v BCD regimen 41–3
 intensified delivery 27, 40–1
v methotrexate-based regimens 27, 35–7
 T10 protocol 27, 43
- cisplatin/doxorubicin/carboplatin (super PLADO),
 in hepatoblastoma 116
- cisplatin/etoposide/vindesine (N5), in neuroblastoma 113
- cisplatin/vinblastine/bleomycin, in malignant germ cell tumour 116
- citrovorum factor rescue 31
- CNS prophylaxis *see* central nervous system directed therapy
- colistin, in neutropenia 512
- COMP chemotherapy
 in NHL 162–3, 166–70, 171–2
see also ADCOMP chemotherapy

- consent, refusal of 163
- COP chemotherapy, in NHL 164, 176
- COPAdm chemotherapy, in NHL 164, 176
- conventionally fractionated radiotherapy (CF-RT),
in ALL 335–9
- corticosteroids, in ALL 303, 466
- CPT-11, in glioma 154
- cranial irradiation
in ALL 271
Berlin–Frankfurt–Munster (BFM)/Dana–Farber
Cancer Institute (DFCI) studies 357–9
Berlin–Frankfurt–Munster (BFM) studies 332–3,
377–8
Brazilian Group study 331–2
Cancer and Leukaemia Group B (CALGB) trials
356–7, 358, 362–5
Children’s Cancer Study Group (CCG) studies
327–9, 344–9, 359–62, 365–73
CLCG–EORTC trial 374–5
GDR Haematology and Oncology Working Group
study 355–6
Japanese Children’s Cancer and Leukaemia Study
Group 376
Medical Research Council trial 330–1
Ortego *et al* study 350–1
Southwest (Pediatric) Oncology Group studies
340–1, 341–4, 352–5
Tokyo Children’s Cancer Group study 334
in AML 228
long-term effects 271
in NHL 167, 170, 172, 185–6
see also craniospinal irradiation
- craniospinal irradiation
in ALL 327–9, 335–9, 345–8
in AML 233, 244
long-term effects 130
in medulloblastoma 126–7, 130, 133–4, 146–7
plus other chemotherapy regimens 136–7, 137–9,
139–40, 142–3
reduced dose 134–6, 141–2
“sandwich” schedules 129, 134–6, 139–40
see also cranial irradiation
- CVPP chemotherapy, in Hodgkin’s disease 200, 207,
209–10
- cyclophosphamide
in ALL 279
in AML 502
BMT conditioning 243, 246, 247
induction therapy 228, 230, 233, 238
in Ewing’s sarcoma 49, 50, 60–1, 518, 543
in glioma 154
in medulloblastoma 142, 143
in neuroblastoma 101–4, 104–6, 109–10, 113,
504, 527
in NHL 164, 165, 170–1, 174, 185–6, 192, 495
in osteosarcoma 31–3, 34–5
in rhabdomyosarcoma 9–11
in Wilms’ tumour 77–80, 86–8
see also bleomycin/cyclophosphamide/actinomycin D;
COMP chemotherapy; LSA2-L2 chemotherapy;
“Total B” chemotherapy regimen; *vincristine-*
containing regimens
- cyclophosphamide/doxorubicin, in neuroblastoma
95–6, 108
- cyclophosphamide/doxorubicin/vincristine (CADO),
in neuroblastoma 109–10
- CYM chemotherapy regimen 164, 175–7
- cytarabine *see* cytosine arabinoside
- cytogenetic analysis 270–1
- cytosine arabinoside (ARA-C, cytarabine)
in ALL 279
in AML 250, 254, 255
ABMT conditioning 241
induction therapy 223, 224, 227–9, 236–9
intrathecal delivery 230, 240, 243, 245–6
post remission consolidation therapy 224
in APL 263
in glioma 153
in medulloblastoma 144–6
in NHL 164, 166, 178–80, 181
see also ADE chemotherapy; DAT chemotherapy;
DCTER chemotherapy; LSA2-L2 chemotherapy;
triple intrathecal therapy
- dacarbazine
in ALL 504
see also ABVD chemotherapy
- dactinomycin *see* actinomycin D
- DAT chemotherapy, in AML 233–6, 240–1, 242
- daunomycin
in NHL 166
see also LSA2-L2 chemotherapy
- daunorubicin (DNR)
in ALL 466, 476, 487
in AML 223, 227–9, 236–9, 254, 255
in NHL 164, 166–8, 177–8
see also ADE chemotherapy; DAT chemotherapy;
DCTER chemotherapy; LSA2-L2
chemotherapy
- DCTER chemotherapy, in AML 223, 229–33
- dexamethasone
in ALL 283–5, 295, 303, 356–7, 466
in AML 223, 236, 255
see also DCTER chemotherapy

- dexrazoxane (DXN)
 in ALL 538–42
 in sarcoma 542–7
- differentiating agents, in neuroblastoma 97–8, 101–4, 110–11
- doxorubicin (Adriamycin)
 in ALL 303, 335, 527, 538–42,
 in AML 228
 in Ewing's sarcoma 49, 51–3, 53–5, 60, 62
 in hepatoblastoma 115, 116
 in Hodgkin's disease 200–1, 209, 210–12
 in MGCT 121
 in neuroblastoma 95–6, 101–4, 109–10, 113
 in NHL 164, 170–1, 174, 185–6, 192
 in osteosarcoma 29, 31–3, 34–5, 39–40, 46
 intra-arterial delivery 33–4
 in rhabdomyosarcoma 7–9, 9–11, 12–14, 14–16
 in sarcoma
 doxorubicin treated 542–47
see also ABVD chemotherapy; cisplatin/doxorubicin;
 cyclophosphamide/doxorubicin; *vincristine-*
containing regimens
- doxorubicin/vincristine/prednisolone/L-
 asparaginase/methotrexate/intrathecal cytarabine,
 in ALL 335
- drug resistance, in neuroblastoma 95–6
- DTIC, in soft tissue sarcoma 19–20
- economic evaluation, GCSF 488–90
 in ALL 488–90
 in autologous peripheral blood progenitor cell (PBPC)
 transplantation 501–4
- echocardiography (ECHO) investigation
 in ALL 548
 before doxorubicin 549
 after doxorubicin 550
- 8-in-1 regimen
 in glioma 152, 156–7
 in medulloblastoma 129, 139–40
- encephalitis, viral 427
- encephalopathy, in ALL 357
- endocrine problems, secondary 130
- ependymoma
 Children's Cancer Group/Radiation Therapy
 Oncology (CCSG–RTOG) study 137–9
 International Society of Paediatric Oncology (SIOP)
 studies 127–8, 133–4
 Pediatric Oncology Group studies 140–1, 161
 Southwest Oncology Group study 143–4
- epiadriamycin, in Wilms' tumour 67
- epipodophyllotoxins, in neuroblastoma 95
- epirubicin, in neuroblastoma 96, 108–9
- epoetin alfa, in chemotherapy-related anaemia 533–5
- Erwinia* asparaginase
 in ALL 319, 324
 in lymphoid malignancies 187–9
- Erwinia chrysanthemi*, in ALL 269
- Erbitux, in glioma 154
- Escherichia coli* asparaginase
 in ALL 312, 319, 324
 in lymphoid malignancies 187–9
- etoposide (VP-16)
 in ALL 279, 466, 476, 487, 504
 in AML 250, 255
 BMT conditioning 240–2, 242–4
 induction therapy 223, 224, 227–9, 233–6, 244
 in APL 263
 in Ewing's sarcoma 49, 59–60, 62
 in glioma 153, 154, 160–1
 in Hodgkin's disease 200, 209–10
 in medulloblastoma 144–6
 in neuroblastoma 96, 98–9, 101–4, 109–10, 527
 in osteosarcoma 27–8
 in rhabdomyosarcoma 3–4, 12–14, 17–18
see also DCTER chemotherapy
- erythropoietin (EPO), in neuroblastoma 527
 St. Jude's Children's Research Hospital study, NB 91
 protocol 527–30
- Ewing's sarcoma 49–60
 American Children's Cancer Group and Paediatric
 Oncology Group 63–5
 Children's Cancer Group and Paediatric Oncology Group
 study 62–3
 CCG-7942 study 50
 EUROEWING'S study 50
 European Intergroup Collaborative Ewing's Sarcoma
 Study Group (EICESS) 50
 German Cooperative Ewing Sarcoma Study (CESS)
 50, 55–7
 Intergroup Ewing's Sarcoma Study 1 (IESS1) 49, 51–3
 Intergroup Ewing's Sarcoma Study 2 (IESS2) 49, 53–5
 Intergroup Ewing's Sarcoma Study 3 (IESS3, CCG
 Intergroup) 50, 59
 Pediatric Oncology Group study 49–50, 57–9
 St. Jude Children's Research Hospital 60–61
- febrile neutropenia (FBN) 485, 486
 Children's Oncology Group study 508–11
 in NHL 496–7
- 5-fluorouracil (5FU), in hepatoblastoma 115, 118–20
- folinic acid (FA) rescue 135, 136, 363, 423
- ganglioglioma, anaplastic 152, 156–7
- gastrointestinal toxicity
 in AML 249
 in medulloblastoma 139–40

- gastrointestinal toxicity (*Contd*)
 in NHL 185–6
 in Wilms' tumour 85–6
- G-CSF *see* granulocyte colony stimulating factor
- gene rearrangements
 in Ewing's sarcoma 50
 in NHL 185–6
- germ cell tumour, malignant 115, 116–7
- girls, duration of ALL therapy 274, 401, 403, 407
- glioblastoma multiforme (GBM) 150
 chemotherapy 140–1, 151–3, 156–7, 158–60
 radiotherapy 157–8
 surgery 150–1
- glioma 150–61
 chemotherapy 151–3
 Children's Cancer Group (CCG) studies 150–4, 156–7, 158–9
 future studies 153–5
 North American Brain Tumour Consortium 153
 Pediatric Oncology Group (POG) studies 151, 153, 157–8, 161
 radiation therapy 151
 surgery 150–1
- glucocorticoid receptors, in ALL 268
- glutamine and glutamic acid, in ALL 316–17
- granulocyte colony stimulating factor (GCSF)
 in ALL 459, 484, 486, 491, 499
 Children's Cancer Group Study 459–66
 FRALLE 93 trial 466–71
 Total Therapy Study XIII A 476–81
 Pediatric oncology group study No.9398 482–4
 Medical Research Council (MRC) UKALL XI trial 484–6, 486–8
 Berlin-Frankfurt-Munster study group 491–4
 Associazione Italiana di Ematologia Oncologia Paediatrica (AIEOP) protocol 499–501
 in AML 230, 247
 in neuroblastoma 101, 109
 in non-Hodgkin's lymphoma (NHL) 486, 494
 Medical Research Council (MRC) UKALL XI trial 486–8
 French Society of Pediatric Oncology study 494–8
 Japanese Cooperative Study Group protocol 504–8
 in osteosarcoma 28
- granulocyte-macrophage colony stimulating factor (GMCSF)
 in chemotherapy-induced neutropenia 512–14, 514–18
 German Pediatric Oncology/Hematology Group protocols 524–6
- granulocytic sarcoma 227, 242
- growth hormone deficiency 130
- haematological toxicity
 in ALL 341, 437
 in AML 236
 in febrile neutropenia (FBN) 479, 486, 488
 in Hodgkin's disease 216
 in medulloblastoma 139
 in metastatic rhabdomyosarcoma 21–2
 in NHL 162, 168, 171
 GMCSF role 518–24
see also infections; neutropenia; sepsis
- HAM chemotherapy, in AML 227
- hematopoiesis, in neuroblastoma 527
- hemopoietic colony stimulating factors
 erythropoietin (EPO) 527
 granulocyte colony stimulating factor (GCSF) 459
 granulocyte-macrophage colony stimulating factor (GMCSF) 512
- hearing loss *see* ototoxicity
- hepatic toxicity
 in AML 249, 250
 in neuroblastoma 102–3, 115
 in NHL 185
 in sarcoma 543
 in Wilms' tumour 86
- hepatoblastoma (HBL) 115–16
 Children's Cancer Group (CCG) trial 115, 118–19
 SIOPEL studies 115–16
- hepatocellular carcinoma (HCC)
 Paediatric Oncology Group/Children's Cancer Study Group 120–1
- herceptin 28
- herpes zoster infection 137, 208–9
see also varicella zoster infection
- high-dose methylprednisolone (HDMP), in ALL 279
- histiocytic lymphoma 167
- Hodgkin's disease 199–225
 ABVEPC 201
 Buenos Aires Group study (Sackmann-Muriel *et al*) 200, 209–10
 Children's Cancer Group (CCG) studies 199–200, 203–5
 Children's Oncology Group study 215–17
 Cochrane review 214
 COGAHODOO31 trial 201
 Cramer & Andrieu study (France) 200, 207
 French Society of Paediatric Oncology (Oberlin *et al*) 98, 208, 209
 Gehan *et al* Intergroup study 201, 212–14
 long term sequelae 199–200
 Sullivan *et al* study (Pediatric Oncology Group) 200–1, 210–12
 Tata Memorial Hospital 217

- Weiner *et al* study (Pediatric Oncology Group) 200, 205–7
- hydrocortisone
in medulloblastoma 127, 144
see also triple intrathecal therapy
- hydroxyurea 166
see also LSA2-L2 chemotherapy
- hyperfractionated radiotherapy, IRS-IV 22
in ALL 335–9
- ICRF-187 542–7
doxorubicin-treated sarcoma patients 542, 546
- ¹³¹I-metaiodobenzylguanidine (¹³¹I MIBG), in neuroblastoma 95
- idarubicin
in AML 227–9
in APL 263
- ifosfamide
in Ewing's sarcoma 49, 50, 59, 60
in glioma 153–4
in medulloblastoma 144–6
in neuroblastoma 95, 96, 101–4, 108–9
in osteosarcoma 28, 46
in rhabdomyosarcoma 4, 17–18
- ifosfamide with mesna and etoposide (IE)
in Ewing's sarcoma 518
in metastatic rhabdomyosarcoma 20–2
in sarcoma, doxorubicin treated 543
- ifosfamide/vincristine/doxorubicin (IVAd), in malignant germ cell tumour 116
- immunotherapy, in osteosarcoma 28
- infections
in ALL 427, 460, 462, 476
in AML 229
in hepatoblastoma 119
in Hodgkin's disease 210
in NHL 171, 184–5
see also sepsis; specific infections
- infertility, in Hodgkin's disease 200
- intellectual (IQ) deficit
in ALL 351, 365
in medulloblastoma 130
- interferon, in osteosarcoma 28, 29, 30
- interferon alfa, in neuroblastoma 113, 527
- intra-arterial drug delivery, in osteosarcoma 28, 31, 33–4, 39–40
- intrathecal chemotherapy
in ALL 341–4, 350–1
in AML 232, 240, 242, 244–5
in medulloblastoma 127, 143–4
triple agent *see* triple intrathecal therapy
see also intrathecal methotrexate
- intrathecal cytarabine (IT ARA-C), in ALL 335
- intrathecal methotrexate (IT MTX)
in ALL 271–2, 279, 319, 335, 460, 485, 515
Berlin–Frankfurt–Munster (BFM) studies 377–8
Cancer and Leukaemia Group B (CALGB) trials 356–7, 362–5
Children's Cancer Study Group (CCG) studies 344–5, 359–62, 370–4
CLCG-EORTC trial 374–5
GDR Haematology and Oncology Working Group study 355–6
Ortega *et al* study 350–1
in radiotherapy trials 327–31, 332–3
South West (Pediatric) Oncology Group studies 341–4, 352–5
in medulloblastoma 127, 142, 143, 144
in T-NHL 485
see also triple intrathecal therapy
- ipropilatin
in glioma 153, 161
in neuroblastoma 96, 108–9
- irinotecan, in glioma 154
- irinotecan (CPT11) with vincristine, in Rhabdomyosarcoma (RMS) 5
- JEB regimen, in malignant germ cell tumour 116
- KL-1 antigen (CD30) 165
- large cell lymphoma 163, 182, 183
anaplastic 165
APO regimen 193, 194
Paediatric Oncology Group Phase III trial 193–4
- leucopenia 153
- Leukovorin, in B-cell neoplasms 195
- leukaemia
acute lymphoblastic *see* acute lymphoblastic leukaemia
acute myeloid *see* acute myeloid leukaemia
T cell 163, 164, 172–4, 182–5
- leukencephalopathy
in ALL 373
in medulloblastoma 127, 136, 146
- liver metastases, in Wilms' tumour 78–9
- liver toxicity *see* hepatic toxicity
- LMB 86 chemotherapy, in NHL 175–7
- lomustine
in medulloblastoma 131
in glioma 153
- loss of heterozygosity, in Wilms' tumour 67
- LSA2-L2 chemotherapy, in NHL 163–4, 171
v A-COP regimen 164, 170–1
v ADCOMP regimen 164, 177–8
v COMP regimen 162, 166–8, 169–70

- lung irradiation
 in Ewing's sarcoma 49–50, 51–3
 in osteosarcoma 34–5
 in Wilms' tumour 77
- lung metastases
 in Ewing's sarcoma 49
 in osteosarcoma 28
- lymphoblastic lymphoma 163, 164, 165
 Children's Cancer Study Group (CCSG) studies 166–8,
 171, 172, 177–8
 EORTC 5888 trial study 186–7
 EORTC 58881 trial study 187–9
 Pediatric Oncology Group (POG) studies 170–1,
 174–5, 180–2, 182–5
see also acute lymphoblastic leukaemia
- lymphoma
 B cell 164, 175–7
 Burkitt 167, 175, 178
 histiocytic 167
 large cell 163, 165, **183**
 lymphoblastic *see* lymphoblastic lymphoma
 non-Hodgkin's *see* non-Hodgkin's lymphoma
 small non-cleaved cell 163, 175, 178, 182
 T cell 129, 164, 172–4
see also Hodgkin's disease
- malignant germ cell tumour (MGCT) 115, 116–17
 Paediatric Oncology Group 3049 and Children's Cancer
 Group 8882 121–4
- mannitol, in glioma 153, 160
- mediastinal irradiation
 in NHL 163–4, 172–4
 in Wilms' tumour 77
- medulloblastoma 125–49
 Chang staging system 125
 chemotherapy 126
 Children's Cancer Group (CCG) studies 127, 128,
 129–30, 139–40, 160–1
 Children's Cancer Group/Pediatric Oncology Group
 study 130, 141–2
 Children's Cancer Group/Radiation Therapy
 Oncology Group (CCCG-RTOG) study 127,
 128, 137–9
 future research issues 131–2
 German GPOH group study 129, 144–6
 International Society of Paediatric Oncology (SIOP)
 trials 127, 130–1, 133–6
 Padova Group study 142, **143**
 Pediatric Oncology Group studies 129–30, 161
 prognostic factors 125
 radiotherapy *see* radiotherapy (RT), in
 medulloblastoma
- randomized clinical trials 127–31
 Southwest Oncology Study Group 127, 143
 surgery 125–6
- methylphalan
 in neuroblastoma 93–4, 101–4, 104–5, 110–11
 in rhabdomyosarcoma 4
 in solid tumors 502
- 6-mercaptopurine
 in ALL 295
 in AML 250
 in APL 263
- 6-mercaptopurine (6 MP) *v* 6-thioguanine, in ALL
- 6-mercaptopurine/methotrexate continuing therapy
 in ALL 272
 duration studies 403–6, 408–13, 417–18
 varying methotrexate doses and routes 423–5
 varying schedules of therapy 426–31
 vincristine/prednisolone pulse therapy *see* vin-
 cristine/prednisolone pulses
- in NHL 170–1, 174, 182
- methotrexate (MTX)
 in ALL 279, 423–5, 466, 476, 482, 499
 continuing therapy *see* 6-mercaptopurine/
 methotrexate continuing therapy, in ALL
 high dose intravenous 429–32
 intermediate dose intravenous 355–6, 357–9,
 362–5, 377–8
 intramuscular 423–4
 in B-cell neoplasm 195
 in Ewing's sarcoma 531
 intrathecal *see* intrathecal methotrexate; triple
 intrathecal therapy
- in large cell lymphoma 193, 194
 in medulloblastoma 134–6, 144–6
 in NHL 165, 170–1, 174, 182, 185–6
 in osteosarcoma 28, 46
 EOI studies 27, 35–7
 EORTC study 27, 34–5
 German COSS study 29, **30**, 39–40
 Instituto Rizzoli study 37–8
v intra-arterial cisplatin 31, **32**
 Mayo Clinic study 29
 Paediatric Oncology Group (POG) study 31–3
 T10 protocol 27, 33–4
see also COMP chemotherapy; LSA2-L2
 chemotherapy; 6-mercaptopurine/methotrexate
 continuing therapy; "Total B" chemotherapy
 regimen
- in T-cell leukemia 482
- methotrexate/6 mercaptopurine, in ALL 482
- methylprednisolone, in ALL 269
- ¹³¹I-MIBG therapy, in neuroblastoma 99, 110–11

- mitoxantrone (MTZN)
 in AML 224, 227–9, 250
 in APL 263
- molecular genetics 270
- MOPP chemotherapy
 in Hodgkin's disease 199–201, 207, 208–9
 plus ABVD with total nodal irradiation 200, 205–7
 plus ABVD *v* ABVD plus radiotherapy 199–200, 203–5
 plus bleomycin 200–1, 210–12
 plus involved field *v* extended radiotherapy 201, 212–14
 in medulloblastoma 128, 136–7, 140–1
- MTTPE immunotherapy, in osteosarcoma 28
- mucositis, in NHL 185–6
- muramyl tripeptide (MTP), in osteosarcoma 46–8
- mustine *see* nitrogen mustard
- MYCN* (*NMYC*) gene amplification 94–5, 101, 102
- myeloablative therapy
 in neuroblastoma 95, 113
- myelodysplastic syndrome (MDS) 227, 233, 244–5
- myelosuppression
 in ALL 491–4, 499–501
 in AML 229, 233
 in glioma 157
 in hepatoblastoma 118–20
 in medulloblastoma 140–1
 in NHL 185
- N5 chemotherapy, in neuroblastoma 113
- nephrotoxicity *see* renal toxicity
- neuraxial irradiation *see* craniospinal irradiation
- neuroblastoma 93–114
 acute and late effects of therapy 98–9
 Children's Cancer Group (CCG) studies 93–4, 94–5, 96–7, 98, 101–4
 Children's Oncology Group (COG) study 98, 99
 dose intensification 93–5
 European Neuroblastoma Study Group (ENSG) 94, 96, 99, 104–6, 110–11
 French Society of Paediatric Oncology study 98–9, 109–10
 future research needs 99
 German Society of Paediatric Oncology and Hematology 111–13
 local control 96–7
 minimal residual disease 97–8
 newer cytotoxic agents 95–6
 Pediatric Oncology Group (POG) studies 93–4, 97, 106–8
 neuropsychological sequelae, cranial irradiation 351, 365
 St. Jude's Children's Research study 113–14
 neurotoxicity
 in glioma 157
 in Wilms' tumour 85–6
- neutropenia
 in ALL 516
 in AML 228, 229
 in Ewing's sarcoma 520
 in glioma 161
 in Hodgkin's disease 205
 in neuroblastoma 110
 in NHL 174–5
 in solid tumor malignancies 513–14
 in Wilms' tumour 85–6
see also haematological toxicity; infections; sepsis
- NHL *see* non-Hodgkin's lymphoma
- nitrogen mustard (mustine)
 in medulloblastoma 129, 136–7, 140–1
see also MOPP chemotherapy
- N6 chemotherapy, in neuroblastoma 113
- non-Hodgkin's lymphoma (NHL) 162–98
 Children's Cancer Study Group (CCSG) studies 162–3, 166–70, 136–7, 177–8
 French Paediatric Oncology Society (SFOP) study 175–7
 localised 162–3, 165
 LSA2-L2 *v* COMP chemotherapy 167, 168, 169–70
 omission of involved field radiotherapy 174–5
 short 9 week chemotherapy regimen 180–2
 shortened duration of therapy 171–2
 lymphoblastic *see* lymphoblastic lymphoma
 Pediatric Oncology Group (POG) studies 162–5
 St Jude Children's Research Hospital study 185–6
 secondary, in Hodgkin's disease 206–7
 UK Children's Cancer Study Group (UKCCSG) study 163–4, 172–4
- non-lymphoblastic lymphoma
 Children's Cancer Group study 189–91
 Paediatric Oncology Group study 191–3
- non-metastatic medulloblastoma
 International Society for Pediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 147–9
- non-metastatic osteosarcoma
 Paediatric Oncology Group Study POG-8651 45–6
- NY I and NY II chemotherapy regimen, in ALL 459, 461
- oligodendroglioma, anaplastic 150, 152, 156–7
- OPEC chemotherapy, in neuroblastoma 104–6, 110–11

- OPP chemotherapy, in medulloblastoma 129, 140–1
 osteosarcoma 26–48
 CCG and POG 46–8
 Children's Cancer Group (CCG) study 27–8
 EORTC study 27, 34–5
 European Osteosarcoma Intergroup (EOI) studies 27, 35–7, 40–1
 German COSS group studies 27, 29, 30, 39–40, 41–3
 Italian Institute Rizzoli group study 27, 37–8
 Mayo Clinic study 26–7, 29–31
 MD Anderson Hospital study 31, 32
 Memorial Sloan-Kettering Hospital studies 26–7, 43–4
 Multi Institutional Study (MIOS) 27
 Pediatric Oncology Group study 31–3
 Rosen T10 protocol 26–8, 33–4, 43–4
 UCLA study 27, 33–4
 Ototoxicity
 in hepatoblastoma 115–6
 in malignant germ cell tumour 116, 117
 in medulloblastoma 140
 in neuroblastoma 98–9, 109–10
 pancreatitis
 in ALL 300–2, 308
 in NHL 185
 paraparesis, transient 351
 PCV chemotherapy *see* procarbazine/CCNU/vincristine
 PEG asparaginase *see also* polyethylene glycol conjugated asparaginase (pegaspargase), in ALL
 peripheral stem cell transplantation (PBSCT), in ALL 504
 pirarubicin, in ALL 504
 platinum compounds
 in glioma 153, 161
 in neuroblastoma 94–6
 see also carboplatin; cisplatin; iproplatin
 PNET *see* primitive neuroectodermal tumour
Pneumocystis carinii (PCP) infection 468, 478, 485, 487, 492, 499
 co-trimoxazole 485, 502
 nystatin 492
 pneumonia
 in ALL 409
 in medulloblastoma 140
 pneumonitis
 in medulloblastoma 140–1
 in neuroblastoma 102–3
 in NHL 186
 in Wilms' tumour 81
 polyethylene glycol conjugated asparaginase (pegaspargase), in ALL 312
 polymerase chain reaction (PCR), in neuroblastoma 98
 pontine glioma, intrinsic *see* brain stem, glioma
 prednisolone/prednisone
 in ALL 285, 295, 302, 356–7, 432, 460, 466, 476, 485, 541
 see also vincristine/prednisolone pulses (in ALL)
 in AML 228, 241
 in Hodgkin's disease 199, 200, 209–10
 in NHL 170–1, 174, 185–6, 192, 495
 see also COMP chemotherapy; CVPP chemotherapy; MOPP chemotherapy; OPP chemotherapy; vincristine/CCNU/prednisone; vincristine/prednisolone pulses
 primitive neuroectodermal tumour (PNET) 153, 154, 160–1
 supratentorial 125, 129, 131–2, 139–40
 probutol, in cardioprotection 456
 procarbazine
 in glioma 158–60
 in medulloblastoma 134–6
 see also CVPP chemotherapy; MOPP chemotherapy; OPP chemotherapy
 procarbazine/CCNU/vincristine (PCV), in glioma 152, 156–7
 proctitis 57
 pulmonary toxicity, in Hodgkin's disease 205
 PVB regimen, in malignant germ cell tumour 116
 R115777 (Zarnestra), in glioma 154
 radiation sensitisers, in glioma 154
 radiotherapy (RT)
 in ALL 327–34
 cranial *see* cranial irradiation
 craniospinal *see* craniospinal irradiation
 in Ewing's sarcoma 49–50
 field *v* whole bone 49–50, 57–9
 hyperfractionation 49, 55–7
 in glioma 151–2
 with chemotherapy regimens 152, 156–7, 158–60
 hyperfractionation 151–2, 157–8
 in Hodgkin's disease
 after CCVP *v* AOPE 200, 209–10
 Cochrane review 214
 involved *v* extended field plus MOPP 200–1, 212–14
 mantle *v* involved field 200, 207
 plus ABVD chemotherapy 200–1, 203–5
 plus alternating MOPP and ABVD 200–1, 205–7
 reduced dose 200, 208–9
 in medulloblastoma 126, 131
 see also craniospinal irradiation, in medulloblastoma
 in neuroblastoma 96–7, 98–9, 106–7
 in NHL 185–6
 with A-COP chemotherapy 162, 170–1
 in COMP *v* LSA2-L2 study 166

- omission in localised disease 163, 174–5
 - in T cell leukaemia/lymphoma 163–4, 172–5
- in osteosarcoma 28, 33–4, 34–5
- in rhabdomyosarcoma 5, 7–9, 14–16
- in Wilms' tumour 66, 68–9, 69–70
 - stage I/II/favourable histology 66, 71–3, 74–6, 77–80
 - see also* total body irradiation
- ranimustine (MCNU), in ALL 504
- recombinant human erythropoietin (rhEPO), effect
 - in chemotherapy-induced anaemia 531–533
 - in sarcoma 535–7
- refractory anaemia with excess of blasts 233
- remission induction therapy, in ALL
 - St. Jude's Total Therapy Study XI protocol 279–83
- renal toxicity 244–5
 - in hepatoblastoma 115–6, 119
 - in malignant germ cell tumour 116
 - in medulloblastoma 140, 149
 - in neuroblastoma 98–9, 102–3, 109–10
- 13-cis-retinoic acid, in neuroblastoma 96–7, 101–4, 110–1
- rhabdomyosarcoma (RMS) 3–25
 - difficulties in reviewing trials 3
 - German Co-operative Group (CWS) 3, 5
 - Intergroup Rhabdomyosarcoma Study Group (IRSG, now COG) studies 3, 4, 5, 7–14, 17, 18, 20
 - Intergroup Rhabdomyosarcoma Study Group (IRS-IV) 22–23
 - International Society of Paediatric Oncology (SIOP) MMT studies 3, 4, 5, 6, 14–16
 - Italian Co-operative Group (ICG) study 3, 5, 16
 - lessons from non-RMS soft tissue sarcoma 6
 - lessons from RMS studies 5–6
 - treatment approach 5
- Rituximab, in NHL 165
- r-metHuGCSE, in neutropenia 482
- RMP-7, in glioma 154
- RT-PCR technique, in neuroblastoma 98

- “sandwich” chemotherapy, in medulloblastoma 129, 134–6, 139–40, 144–6
- second malignancy
 - in ALL 365, 409
 - in Hodgkin's disease 200, 206–7, 210–11, 213–14
 - in medulloblastoma 133–4
 - in neuroblastoma 99–100, 103, 111
 - in NHL 162, 170, 182
 - ADCOMP regimen and 163, 178
 - high dose asparaginase and 164, 184, 185
 - radiotherapy and 126
- seizures 351, 373

- sepsis
 - in Hodgkin's disease 206, 207, 210
 - in medulloblastoma 144, 146, 149
 - in NHL 171, 181–2, 185
 - see also* infections
- sex differences, duration of ALL therapy 400–1, 403, 404, 407
- sibling donors, histocompatible 224
- sildenafil, in cardioprotection 456
- skin toxicity, in neuroblastoma 102–3, 111
- small non-cleaved cell lymphoma 163, 175, 178–9, 181–2
- soft tissue sarcoma (STS) 3
 - lessons for rhabdomyosarcoma 5–6
 - Pediatric Oncology Group (POG) studies 18–19, 19–20
 - see also* rhabdomyosarcoma
- stem cell rescue
 - in AML 233–4
 - in glioma 154
 - in malignant germ cell tumour 116–7
 - in neuroblastoma 95
 - see also* autologous bone marrow transplant
- steroids
 - in ALL 268–9, 279
 - toxicity 292, 294
 - in medulloblastoma 126–7, 128, 143–4
 - see also* dexamethasone; hydrocortisone; prednisolone/prednisone
- stomatitis
 - in hepatoblastoma 118–9
 - in rhabdomyosarcoma 16
- SU5416, in glioma 154

- T cell leukaemia/lymphoma 163–4, 165, 172–4, 182–5
- temozolomide
 - in glioma 154
 - in GBM 154
- teniposide
 - in neuroblastoma 95–6, 108
 - in solid tumors 525
- testicular disease, in ALL
 - CNS directed therapy studies 350, 354, 362
 - duration of therapy studies 400–1, 403
- testicular tumours 116
- thioguanine (6-TG)
 - in ALL 272, 436–7, 432, 504
 - in AML 223, 224–5, 228, 233–6, 244–5, 255
 - in APL 263
 - in NHL 166
 - see also* DCTER chemotherapy; LSA2-L2 chemotherapy
- thiopurines
 - in ALL 436–7
 - see also* 6-mercaptopurine; thioguanine

- thrombocytopenia
 in ALL 436
 in NHL 184
- thyroid deficiency 13
- topoisomerase inhibitors, in neuroblastoma 95
- topotecan, in glioma 154
- “Total B” chemotherapy regimen, in NHL 165, 178–80
- total body irradiation
 in AML 233, 238, 244–5, 255
 in neuroblastoma 94, 101–3
- total nodal irradiation, in Hodgkin’s disease 200, 205–7
- translocations, in Ewing’s sarcoma 50
- trimethoprim-sulfamethoxazole, in ALL 478, 487, 492, 499
- triple intrathecal therapy
 in ALL
 Pediatric Oncology Group study (AlinC-12) 352–5
 Southwest Oncology Group study (AlinC-9) 340–1
 in AML 233, 244–5
 in NHL 181
- tuberculosis 205
- tumor apoptosis, in osteosarcoma 48
- varicella zoster infection 137, 108–9, 409, 427
see also herpes zoster infection
- veno-occlusive disease
 in neuroblastoma 102–3
 in Wilms’ tumour 85, 86
- vinblastine
 in Hodgkin’s disease 207
 in malignant germ cell tumour 116
see also ABVD chemotherapy
- vincristine (VCR)
 in ALL 279, 303, 432, 466, 476
 in AML 228
 in Ewing’s Sarcoma 62
 in glioma 153–4, 156–7
 in hepatoblastoma 115, 118–20
 in Hodgkin’s disease 200–1
 in medulloblastoma 127
 German GPOH study 129, 144–6
 International Society of Paediatric Oncology (SIOP) trials 127, 133–4, 134–6
 Padova Group study 142, **143**
 Southwest Oncology Study Group study 126–7, 143–4
 in neuroblastoma 104–6, 109–10
 in NHL 164, 170–1, 174, 185–6, 303, 432, 466, 476
 in osteosarcoma 30–1, 34–5
 in Wilms’ tumour 74–6, 91
see also COMP chemotherapy; CVPP chemotherapy; LSA2-L2 chemotherapy; MOPP chemotherapy; procarbazine/CCNU/vincristine
- vincristine/actinomycin D (VA)
 in rhabdomyosarcoma 3, 5, 7–9, 12–14
 in Wilms’ tumour 66, 69–70, 71–3
 cost of different regimens 78–9
 v either agent alone 74–6
 fractionated v single dose actinomycin D 73
 prolonged preoperative 81–4, 88–9
- vincristine/actinomycin D/cyclophosphamide (VAC)
 in Ewing’s sarcoma 51–3
 in rhabdomyosarcoma 3–6, 21, 22
 International Society of Paediatric Oncology (SIOP) study 14–16
 IRS-I-III studies 7–14
 IRS-IV study 5–6, 17–18
 Italian Multicentre Collaborative Group 16
 in soft tissue sarcoma 18–19
- vincristine/actinomycin D/cyclophosphamide/doxorubicin (VACA)
 in Ewing’s sarcoma 51–3, 53–5, 59–60
 in malignant germ cell tumour 116
 in rhabdomyosarcoma 3–6, 7–11, 12–14
 in soft tissue sarcoma 19–20
 in Wilms’ tumour 77–80, 86–88, **87**
- vincristine/actinomycin D/doxorubicin (AVA)
 in rhabdomyosarcoma 12–14
 in Wilms’ tumour 66, 67, 71–3, 76–7
 cost of different regimens 88–9
 fractionated v single dose actinomycin D 73–5, 81–4, 88–9
 with/without cyclophosphamide 77–80, 86–8
- vincristine and melphalan (VM), in metastatic rhabdomyosarcoma 20–2
- vincristine/CCNU/prednisone
 in glioma 151–2, 158–60
 in medulloblastoma 127, 128, 129–30, 137–9
- vincristine, cyclophosphamide, doxorubicin and methotrexate (COPADM)
 in ALL 466, 490
 in NHL 495
- vincristine/dacarbazine/ifosfamide/doxorubicin (N6) 113
- vincristine/doxorubicin (VAD), in rhabdomyosarcoma 14–16
- vincristine/doxorubicin/cyclophosphamide (VAdrC), in soft tissue sarcoma 18–19
- vincristine, doxorubicin and cyclophosphamide with mesna (VAdriaC)
 in Ewing’s sarcoma 518
 in sarcoma, doxorubicin treated 543
- vincristine/prednisolone pulses (in ALL) 272, 419–22
 Berlin–Frankfurt–Munster (BFM) group studies 421–2
 Children’s Cancer Study Group (CCG) study 419–21
 in duration studies 403–4, 408–16

- vincristine/procarbazine/prednisone (OPP), in
 - medulloblastoma 128, 140, 141
- viral encephalitis 427
- VM-26, in neuroblastoma 104–6, 110–11
- VP-16 *see* etoposide
- vinorelbine with cyclophosphamide, in RMS 5

- Wilms' tumour 66–92
 - anaplastic 79–80, 86–8, 88–9
 - Brazilian Wilms' Tumour Study Group 66–7, 73
 - clear cell sarcoma 79, 88
 - clear cell sarcoma of kidney (CCSK) 89
- International Society of Paediatric Oncology (SIOP)
 - studies 66, 67, 68–9, 85–6, 91–2
- National Wilms' Tumour Study (NWTs) Group studies
 - 66–7, 74–84, 86–8, 88–9, 89–91
 - postoperative chemotherapy 91–2
 - preoperative chemotherapy 66–7, 69–70, 74–6, 85–6
 - rhabdoid 79
 - surgical emergencies 66–7
 - UK Children's Cancer Study Group 66
- ZD1839 (Iressa), in glioma 154

